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Summary 
Since the introduction of cyclosporine into clinical 
practice five years ago, remarkable progress has been made 
in liver transplantation. Patient survival for both adults 
and children has improved from less than 35% at one year and 
20% at 5 years to approximately 70% and 60% respectively. 
The principal indications for transplantation in children 
have been biliary_atresia, postnecrotic cirrhosis, and 
inborn errors of metabolism, with biliary atresia accounting 
for about half the cases. In adults, postnecrotic 
cirrhosis, primary biliary cirrhosis, inborn errors of 
metabolism, sclerosing cholangitis and primary liver tumors 
have been the most frequent reasons for liver replacement. 
Although overall results have been good, there are important 
exceptions. First, transplantation for primary hepatic 
malignancy has been disappointing. Although early survival 
is excellent. most patients eventually have succumbed to 
recurrent tumor, often within one year after operation. 
Only the patients discovered to have an incidental hepatic 
tumor at the time of transplantation for other diseases such 
as postnecrotic cirrhosis have been free of tumor 
recurrence. Second, B-virus antigen carriers transplanted 
for postnecrotic cirrhosis have a high incidence of 
recurrent hepatitis after transplantation. Third, 
transplantation of infants continues to be complicated by a 
high incidence of hepatic artery thrombosis requiring urgent 
retransplantation. 
Retransplantation for allograft rejection, technical 
complications (mostly hepatic artery thrombosis), or primary 
graft failure has been necessary in approximately 20% of 
patients. Survival is nearly 60% in patients retransplanted 
for rejection but is only about 40% for technical failures 
and 25% for primary graft failures. 
Standardized techniques for removal and preservation of 
donor organs and organ implantation have also contributed to 
better results. Donor organs can be safely cooled by rapid 
aortic infusion of cold electrolyte solutions followed by an 
expeditious, bloodless dissection of the liver and en-bloc 
removal of the kidneys. This reduces the risk of warm 
ischemic injury during mobilization of the liver and kidneys 
and significantly reduces the time required to complete the 
donor operation. Routine use of a veno-venous bypass during 
the anhepatic phase of the recipient operation has reduced 
operative blood loss, postoperative renal failure, and 
cardiopulmonary complications and allowed successful 
transplantation of higher risk patients. 
, t J 
Patient selection is based on medical urgency and donor 
suitability as judged by ABO blood group and estimates of 
liver size. Although liver transplantation across ABO blood 
groups is usually successful, results have been best between 
ABO compatible donor-recipient pairs. A positive donor-
specific cytotoxic antibody crossmatch has not been shown to 
be a significant barrier to transplantation of the liver. 
Although liver transplantation is an expensive procedure, 
the cost must be weighed against the considerable cost 
associated with the care of those who would otherwise die of 
end stage liver disease. Rehabilitation after liver 
transplantation has been excellent and most patients return 
to active and productive lives. 
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Since the introduction of cyclosporine into clinical 
practice patient survival for both 
¢ 
has improved from less than 35% at 
adults and children 
i 
~ year and 20% at 
5 years -to approximately 70% and SM~ respectively • 
....J 
The principal indications for transplantation in 
children have been biliary atresia, postnecrotic cirrhosis, 
and inborn errors ot metabolism. In adults, postnecrotic 
cirrhosis, inborn errors of metabolism, sclerosing 
cholangiti~ and primary liver tumors have been the most 
frequent reasons for liver replacement. 
Although overall results ,a.!)lve been good, most tumor 
patients eventually have succumbed to recurrent tumor, I . 
often within one year. B~virus antigen carriers trans~ 
\ 
planted for postnecrotic cirrhosis have a high incidence of 
recurrent hepatitis after transplantation. Transplantation 
of infants continues to be complicated by a high incidence 
of hepatic artery thrombosis. 
Retransplantation for allograft rejection, technical 
complications, or primary graft failure has been necessary 
in approximately 20% of cases. 
Donor organs can be safely cooled by rapid aortic infusion 
of cold electrolyte solutions followed by an expeditious, 
) 
bloodless dissection of the liver and en~bloc removal of 
the kidneys. This reduces the risk of warm ischemic injury 
during mobilization of the liver and kidneys. Routine use of a 
veno~venous bypass during the anhepati~ase of the recipient 
operation has improved graft success. 
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Although liver transplantation across ABO blood 
groups is usually successful, results have been best 
r 
between ABO compatible donor-recipient pairs. A positive 
rJ 
donor~specific cytotoxic antibody crossmatch has not been 
shown to be a significant barrier to transplantation of 
the liver. Rehabilitation after liver transplantation has 
been excellent • .; 
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~F HISTORICAL NOTBS 
The idea of transplanting the liver apparently was conceived first by o. 
Stewart "elch~ in the early 19RM~~K He reported research on transplanting an 
extra liver in a heterotopic site (such as the right paravertebral gutter) 
without disturbing the host liver. All of his experiments were without 
immunosuppression. Orthotopic liver replacement apparently was first 
conceived by Dr. Jack Cannol}'(, but his publication in 1956 .ave no details 
\J",L, -1, ... ( ...) " 
and did not mention if any of his animals (species unspecified) survived. 
,A 
,-- . 
--.,; 
In the summer of 1958, two research pro6{rams on liver replacement were 
established independently, one at the Peter Bent Bri6{ham Hospital in Bostone,--
and the other at Northwestern University in ChicaaroK~ From these first 
efforts, the general requirements tor liver tra~splantationqand the events ot 
rejection in unmodified canine recipients were worked out. V 
Protracted survival in experimental animals atter liver transplantation 
was achieved in Denver in 1963 using azathioprinee,. and BOOn atter using 
ant.ilymphocyte globulin (ALG).e., A number of animals from t.hat original work 
survived tor yearsK~ The longest survivor lived a tull canine lifetime and 
died almost 11 years atter transplantation, having been without 
immunosuppression tor all but 4 months 01 this time. 
,..--
Renal transplantation became a practical for. of treatment. almost 2S 
years ago with the demonstration that azathioprine and steroids were 
synergisticK~ Bmboldened by successes with the kidney, the first clinical 
efforts at liver transplantation were made in aenve~ in March, 1963, followed 
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by similarly unsuccessful single attempts In Boston and in Paris."" The 
,"-./ 
failure of t.he first seven patients to survive tor as lona aa one month caused 
\ 
a moratorium to be declared until 1967. In 1966, ALG was added to the 
immunosuppressive armamentarium with trials in animals and In human kidney 
recipientsAl, U Finally, in 1967,. the first successful liver transplantations 
~ ------- ~ 
were carried out at the University of Colorado under azathioprine, steroida" t/ 
"hCy~ :l\(V;V".e{ -I 
and AidK~ The longest survivor in the world today-is'·now almost 17 yeara.J1···::-'.,.+.n .1 
/'0. 
Throuah the 19TM~I furthe;-successes were achieved with Uver transt 
./ C;.;L.· ¥. . -' 
plantation, but between \ hall and two-rthirds of the recipients died within t.he 
first postoperative yearK~ The operation was 80 unpredictable and unreliable 
that It was justifiably considered to be an experimental operation as opposed 
to a service. This perception was drastically chan"ed with the introduction ot 
the new immunosup~ressive aaent cyclosporine by CaIne et al in 1978 ~ 
_ P:~ r-' 
tlnd with systematic combination of this aaent. with predn1soneK~ The first 
j-:.: 
reports of nearly 80% -one year survival of Uver recipien~ when this drUif 
.\ ~KDFlt? 
was combined with low doses ot steroids ~ been confirmed as t.he number. 
h~If<D . ~ 
of cases fl~s Increased in the ensulna year .. ~ 
At t.he same t.Ime, technical improvements have played a siatniticant role. 
~K i V,","· ,l_ 
It became obvious t.hat optimal biliary tract reconstruction ... anastomosis of 
t"\ 
the donor and recipient ducts over a T-tube (or slent) and that the only rea~ 
8<mable alternative was anastomosis of the donor duct. to a defunctionalizecl 
Umb ot jejunum (Roux-en-Y).I!-- These techniques "reaUy reduced bUe fistulas 
and obstructions aa wen as the infectious complications that were resultin" 
trom imperfect draina"e of the bUfary tree. Later, the introduction of non- ,r, 
" /". c/ v,:." 
heparin veno¥venous bypasse~ made the operation a' different. on. ~_ \he 
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high tension procedure which it had been previously. In turn, it became poe,. 
\ 
sible to train younger surgeons who could take the technology to new center. 
tor further development. 
Finally, the development ot techniques tor multiple organ procurement 
fill"" 
proved to be a crucial final step in makinar liver transplantation pract.ical.e-
-'-' L, E~e past 5 yearf~ i~t- a dramatic increase in the transplantation ot 
~ ~ " 
extrarenal orarans. By the end of 1985, 1787 heart, 1441 liver, 381 pancreas or 
I 
islet cell, and '!! I:I_~e~rt;jDlung transplantations bad been performed in the 6 
United States (Fi. ~ l~AFK Approximately 45% of these transplants were done in h::; . 
~ _J 
1985 Ec~:::gBFK ~:- I 
s/Dy_D_~ ~- ....... , 
Tbe institutional resources and technical expertise required for heart 
transplantation are the most available" and heart transplantation programs have 
.:> 
been proliterati~ taster than those for -t~ other ex~arena1 oratans. Pancreas 
I ~ transplanta~ion and heart-lu~ transplantation are still regarded as experi.,. 
I W -
""" (: ," . , " (' J ~ 
mental and remain Hmlted to fnvesUaraUonal programs in a few major univer-r 
/\ -
sity transplant centers. Liver t.ransplantation requires both exceptional surari-+-
cal expertise and institutional support. Nearly balt the liver transplantations 
, 
performed in the United States have been done as part of the Denver;j"'" 
Pittsburarh series, but there bas been a significant increase in the number of 
J programs in the last few years Ep~ylrCF • ./' 
_ A 
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THB IMPACT OF CYCLOSPORINB 
~" 
There can be no doubt that introduction of cyclosporine for clinical im-t 
munosuppression has been the most significant factor in the expansion of liver 
~ ""1-= "~ 
and heart transplantation.I'I._. For orthotopic liver transplantation, ~- year 
~ ,. 
patient survival has risen from 32.9X under conventional immunosuppression 
with azathioprine and high=dose steroids to 69.4% with cyclosporine and low; n 
I P~ 
dose steroids in the aenver~mlttsburKh series EciEI~OFK Only 29 (17.1%) of the 
170 patients who were managed with azathioprine and steroids remain alive, 
9;10 
but nearly all of these patients are surviving more than ten years after 
/\ 
transplantation and are enjoying an excellent quality of life. Of the first 600 
I . 
Denver-Pittsbur,h patients transplanted uslnar cyclosporine, 340 (68.0%) of the 
Ii 
"~ 
patients are alive, including lOB patients more than 3 years after transplanta:" 
tion •. 
~ 
-:# -
For both azathioprine ,and cyclosporine:otreated patients, the major paof 
. A _ 
tient mortality after liver transplantation has occurred within 6 months of 
.t 3.).. , 
transplantation (Fig 2). Patient and graft loss beyond the first year after 
"" 
sur,ery has always been modest. Improved survival after liver transp1anta~ 
tion has to a large extent depended upon effective prevention or treatment of 
b _ 
acute rejection in the first -.Ix mont.hs after transplantation and the major "-I-
~ -
pact of cyclosporine has been to Increase ,raft and patient survival In, this 
•• <r-_ " .,< "i 
. S:, -..) K~K--~KK -J...j':-lG 
critical early period throuarh better control of rejection (m. ~"" and ~ ) ." 
Monoclonal anti-T·-1ymphocyte antibody (Orthoclone lhqK:Ple~D Ortho 
" 
-J ....., 
Pharmaceuticals, Raritan, NJ) has alao provC?Jl highly effective in clinical tran. 
for reversal of acute steroid "resistant cellular rejection In cyclosporme "'n ~ ~ "" " 
treated patientKaK~ Cerilli: Transplant" t· 
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Cyclosporine is a cyclic polypeptide derived trom two strains of tun~ 
It can be administered intravenously or orally. Since absorption of the drug 
is highly variable and is poor in the early postoperative period, it is custom! 
-
ary to give the drug intravenously for the first. few days after transplantat 
tion followed by a period ot combined intravenous and oral therapy with dail7 
;-
monitorinlt of trough serum or blood levels. Cyclosporine is lipid Ulfubl~I and 
'1' 
ita lastrointesUnal absorption is dependent upon bile and bUe aal~ T;:.tube 
r 
clamping is usually followed by a significant increase in cyclosporfne absorpt 
tionK~/ Also, the principal route of elimination of cyclosporine is by hepatic 
metabolism. Drugs such as phenobarbital, phenytoin, and rifampin/, which are 
--' 
potent inducers of hepatic enzymes, can Increase cyclosporine elimination and 
result in reduced blood levels. Erythromycin, an inhibitor ot hepatic enzymes, 
can increase cyclosporine blood levels. Hepatic tuncUon and bUe production 
after liver transplantation are variable- ani th~retore ~ monitoring of drult levels 
.:; ' .. 
is essentiaL 
In general" patients receive 2 mg/kg ot cyclosporine intravenously every 
2 
<&iCht hours immediately after transplantation. As sooo as gastrointestinal 
function permits, oral cyclosporine, 17.5 m.c/kg administered as a divided dose 
twice a day, is begun. Intravenou8 ad-eJnistration can be reduced to twice a 
./:;, ;t.r };-,-
day in many patients GDCe oral therapy -is begun If drult levels are adequate • 
Kg~ ./ ~ -" ' 
Within three to aI& weeks ot transplantation, doses of 10 mit/kg per day are 
~I ,\ /" 
~-t f' -
eontlllOllly all that i. required to aurlntain adequate drug levels. Renal excre+ 
tlon ot cycloaporlne is minimat but the drult I. nephrotoxic. Dosage may have 
J 
to be reduced In patients with renal dysfunct.ion. Cyclosporine fa not removed 
" - .", 
by dialysi.. In patients with aevere renal dysfunction, a ~ -week courH of 
", 
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monoclonal anUbod7 therap7 can permit sparing ot cyclosporine until renal 
function recover .. 
Conventional bacterial Infections are better tolerated with cyclosporfne 
than with azathioprine. This may be due to the selective action of CYT 
closporine on q~lls and to the lower doses of prednisone required ~th cT! 
closporine. Opport.unistic tungal infections, mgKlSr~w~_~ and~~!!a_ 
""'-pneumonias, and viral infections remain as significant problema. 
INDICATIONS FOR TRANSPLANTATION IN ADULTS 
The Indications for liver transplantation in adults and children differ..,; 
-en4 therefore it is useful to consider these groups separately. Of the 2t7 
/-
..) 
adults (patients over 19 years 01 age) in our first 500 cyclosporinectreated 
'\ 
patients, 197 (66.3%) are living~ One-:.year survival is 68.9% and It¥eyear surt 
........ ~ ~Dy 
~KK - ~ -
I vival is 64.8% (FiJt \4A). The most common indications for liver transplantation 
\ In adults have been chronic acUve hepaUUa. primary bniary clrrhoai8, 
~ sclerosing cholangitis, inborn errora of metabolism, and primary liver tumors 
Jc_ i --IK~ rt- (Fig 6). 
- ~f \ j __ .;;" 
-:---./ 
i J.- \ , ' qra_~sp1antation_ for primary liver cancer 
;/ = = == 
The first orthotopic human liver transplantations were done for hepatic 
tumors ~~ could not be treated by au btotal resection. It was hoped that , 
this patient population would be especian,. favorable for transplantat.ion aince ,.. 
...) 
portal hypertension and ita complicationa are usually not present. Although 
early patient aurvival baa been excellent, lone -term patient survival baa been 
/\ 
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poor (Fig 6B) because of a hi,h rate of tumor recurrence in these immunot 
suppressed patients. 
Our experience with transplantation for hepatic malignancy has recently 
./ <:A rl r ,,\! 1" = 
been reviewed by iwatsuk~l~ - None ot the 14 patient.s who were found to 
CV have an coincidental hepatic tumor at. the time of transplantation for other 
If' diseases such as poetnecrotic cirrhosis or biliary atresia,' have died of 
recurrent tumor. An of these lesions would have been suitable for subtotal 
~AKKK[ , s v' h',4 r:~~ -
hepatic resection b8d-llO\- other disease, of the liver, necessitated transplanta. 
/', 
tion. 
----. 
Forty';;nine patients have been transplanted for liver tumors too exten-f 
sive tor conventional subtotal resection, includin, 21 patients transplanted 
I 
using azathioprine-steroids and 28 transplanted with cyclosporine-:steroids. 
,J t. 
Twenty.;;;nlne of these patients were transplanted for hepatocellular carcinomas. 
Thirty.::.two patients survived more than t~ month a after surgery. Tumor 
, ' 
has recurred in 20 patients ESPu~ and the liver graft is frequently the first 
..) c-/--
site of recurrence. Less than half 't.he patients remained tumor free for at 
I K/~I \.1.,,' " .... / I( \,. \ _ ... ' ~ 'f'-
least ~ year. Dowever, 6- ot,1 patients with flbrolamellar hepatoma remained 
, ~ 
free of tumor for more than erte year. Although there is a high ultimate ret 
~ -
currence rate even tor this variant ot hepatocellular carcinoma, palliation .. 
I 
longer lastin,. 
Conventional chem~ and radiotherapy have been used in combination 
with total hepatic resection and transplantation in an effort to improve sur;; 
vtval, but results have .till been poor. ~ gf ou~?4iKg~tients with nonltlb::ot 
~KD - ~"K~ 
lamellar hepatoma treated with ,!driamycin and other chemotherapeutic a,ents, 
• Cerilli: Tr I ansp JntJtion Surgery 
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developed r-ecurrence within a tew months. The immunosuppression necessary 
to prevent graft rejection may accelerate the growth ot extrahepatic nests of 
malignant cells unrecogniv.able at the time ot transplantation. The high incio[ 
dence of recurrence in the graft suggests that these cells are able to home 
back to the favorable environment of the liver-. Never-theless, the high sur~ 
vival of patients with coincidental malignancies demonstrates that long survival 
after transplantation in t.he presence ot a hepatic maliarnancy is possible. 
Even in the patients with unresectable malignancy, si.gnificant palliation can be 
achieved, especially in patients with less aggressive tumors such as tibrot. 
lamellar hepatoma. V 
Cirrhosis 
i / .:- _ Cirrhosis is ~elm~st +~o~K~~n indication tor Dver replacement in adults 
-(Fig ~FK Most ot these are--pet.ient.s wittI chronic active hepatitis, but t.here 
-, I \ 
~ 
are also small numbers ot patients with cryptogenic cirrhosis or Laennec's cJ.r.r 
rhpsis. One ,year survival atter t.ransplantation tor cirrhosis in adults is 61.IXI' 
V __ ,. :IK-~ ..) 
q ..... --::.: ,..-.., 
but;\drops to 50.9% at 3 years EciKC~BFK Until recently, survival tor cirrhoUc 
-patients over 40 Tears ot age has been poo~K but. this appears to relate to the 
coexistence ot other risk factors In these patients rather than an effect of aae 
;;; 
itKselt~ There is a slCniticant incidence of recurrence ot hepatitis in B-virus 
carriers. AlcohoUc patients have alwaTs constituted a hlgh;,rlsk group, since 
-' 
their medical condition is otten poor and recidivism is a constant. concern. 
, 
However, we continue to otfer transplantation to carefully selected candidatea 
with Laennec'. cirrhosla. 
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Primary biliary cirrhosis is the second leading Indication for transplan+ 
'" 
tation in adults. This is an uncommon disease most often affectlnat late middlr-'"' ) A 
aged women. The cause is unknown but i1 is considered to be an autoimmune 
disorder. Fatigue, jaundice, pruritis, hepatomegalTt and osteoporosis ("hepatic 
./ 
rickets") are characteristic features of the disorder,. which may progress over 
-' 
many yeara. There is no effective medical therap~ although a variety of 
..) 
-, 
agents including J).;;peniclllamine, chlorambucil, colchicine, and even coy+, r _ ~K 
-' 
closporine have been tried. A sudden increase in the rate of rise of serum 
bilirubin, progression of osteoporosis, or complications of portal hypertension 
(variceal bleeding, encephalopathy, Intractable ascites) are indications for 
-
transplantation. The risk of recurrence of PDC after transplantation Is un+ 
known~ but the resu~_ 80 far are encouraging. Pitty-eight :£t the 83 patiente 
- , ~hD _ 
transplanted tor PDq, are alive 3 months to 8 years after surgery. Actuarial 
--'" )(" I -~-
survival Is 88.41 at -OA8 and at 5 yeare Ec~ IIU~AFK There have been no deaths 
and no confirmed recurrences of disease among the 42 patients surviving more 
I J 
than one year • 
fi 
Sclerosi!!( cholangitis 
/ -
Sclerosing cholangitis may occur in a primary form or in association 
with other diseases, especially inflammatory bowel disease. It is Il880Clated 
\ with an increased risk of carcinoma of the bUe duct. Many of t~ese patients 
\ 
have had attempte at surgical biliary diversio~ which complicates transplanta1 
tion and should be avoided except in patients with well-defined extrahepatic 
(,,/", -fl,. ~ 
lesions. Survival after transplantation has been improving and is preeent.11·-
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I ~I-
75.'7% at ~ year Eci~·SjAFK The risk ot late recurrence ot disease or late 
development of bile duct cancer after transplantation for sclerosing cholangitis 
is not yet known. It proctocolectomy tor associated bowel disease is indicated, 
it is best deterred until 3 to 6 months after liver transplantation. ./ 
Inborn errors ot metabolism 
---- .,./ -.:. -"(/ -
qwenty~three adult.s D~ere 'transplanted for inborn errors of metabolism" 
, ~ 
including alptui~{ ... antitrypsln deficiency (11 cases), Wilson's disease (8 case.), 
/,'-' 
hemochromatosis (2 cases), tyrosinemia (1 case), and cystic fibrosis (1 case). 
- $. 3s: .i: "'" 
Survival in this group of patients has been aood (FigU-ree' 6A and, 8) with th&-
y . .\ I, " 
" r _ 
except.ten ~ those patients who present in advanced stages 01 hepatic ent 
~ -
cephalopathy with acute hepatic decompensation trom Wilson's disease. 
-Mortality in the encephalopathic patient fs 5OX. 
INDICATIONS FOR TRANSPLANTATION IN CHILDREN 
li --.- -'- ./ ____ . y' \ 
I"'::: . -A c,.'.'; I(! 
One-hundred forty-three ('70.4X) of the 203 children (age: 18 and .:under) 
'--- ---.. (/>',:" tI ~ ".\ 
"\ I~---- ,. ,... .5-" -~~~f D~~~/EKi:rieU ~;::KK Uvin •. 'Vith ~ ~year and -fD~ -year actuarial survival at .10.4% 
and 6'7. ~~ciK ~FK As in adults; most Of' the mortality after Uver trariat 
J.... {I<KK~ '...,. --
plantation in children is in the tirst 6 months after~ surgery. 
Biliarz; atresia 
vi;: 
~rary atresia is the moat eommon Indication tor Uver replacement In 
E~ 'J: 
chUdren (Fig 5). Moat ot these patient. have had prevlou8 operaUon8, usually 
_ ~ ~A _ 
~ ~ porto-o-enterostomle8 (KaBat procedure) and occasionally por~Kyatemic venous 
./ 
shunt., otten with HUle It any benefit. Previous 8urgery in the hepatic hUua 
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makee liver t.ransplantatlon much more difficult. and, for moat chlldren wit.h 
biliary atresia, transplantation 18 the only genuine hope of long term survival • 
. \ 
Oonservative use of portofenterostomy, however, fa st.ill appropriate. There is 
a severe shortage of donors for small children and a successful Kasai 01>1" 
~ -
..) 
eration can stabilize the patient. and buy valuable time. Although previous 
surgery is associated with an increased morbidity after liver transplantation, 
it has not been associated with -a~increased mortality~ However, revisions ot 
Kasal operations and stoma creation are rarely of significant benefit and 
greatly increase the difficulty ot liver transplantation. Portotsystemic venous 
shunts should also be avoided whenever possible. 
',-
The results ot liver transplantation tor biliary atresia are very 
~D /( 
"-I~ 
gratifying and long term survival has been excellent."-'" In our tirst 600 
A , ~ 
-' 
transplantations with cyclosporine, 68 of 99 patients with biliary atresia are 
surviving t~ mo~ths to 6 years after surgery. Actuarial survival is 68.4% 
I S- ~-c-::-: 
at ~ year and 66.7% at fiye years Ec~}FK Only 4 of t.he 65 patients who 
I have survived more than ORe year after transplantation tor biliary atresia 
1\ 
have died. Since only modest doses of prednisone are required with C7! 
-
ClKt~ 
closporine, growth and development in most ot these children 4s essentially 
normaLCY v 
'y"" 
Inborn errors of metabolism 
;;/ -= ./ -= 
;, 
The second most common indication tor liver transplantation in children 
has been inborn errors ot metabolism. Survival after liver transplantat.ion for 
I 
inborn error, of, m~tabo~m ~ In children has been excellent (73.8% at ~ and ~DpI 
~ " 5-= I 0 I -' - 1:. . '-' 
,t\ '. ,,' __ " 
- .j.:;., - ( 
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antitrypsin deficiency (27 cases), Wilson's disease (6 cases), tyrosinemia 
(5 cases), glycogen storage disease (5 cases), hypercholesterolemia (1 case) 
and sea;;;;.blue histiocyte syndrome (1 case). Two patients (one adolescent and 
one adult) have been transplanted for chronic active hepatitis contracted as a 
result of factor VIn therapy for hemophilia,.. and the one survivor (the adoles:! 
./ pd==: ~ 
cent now 14 months .fiftee transplantation) appears to have been cured of his 
I' 
. hemophniaK~ ~ 
I Two years ago a simultaneous heart:;Hver transplant was performed in j ", 
Pittsburgh in a 6 ~year-: old girl with homozygous familial hpercholesterolemiaK~K 
........... She had already required two coronary artery bypass operations and a 
mitral valve replacement for severe arteriosclerotic heart disease; but W811 
failing despite this. A heart transplant was performed followed immediately by 
,j 
a liver transplant from the same donor. Although the liver appeared ,rossly 
!lormal, extensive ~udies ot the child ru:i indicated that the metabolic defect 
responsible tor her disease was a detect in hepatic:::based metabolism. Now 
'" d.... . 
more than ~ years atter the double transplantation, the child is doing well 
and has a sustained improvement in her lipid and cholesterol profreK~ v' 
6 OTHER INDICATIONS IN ADULTS AND CHILDREN 
Most. of the other pediatric liver transplantations in the DenverJ r-. 
1\/ 
Pittsburgh series have been done for cirrhosis (21 cases), familial cholestasls 
(14 cases), and neonatal hepat.it.is (.iant cell hepatitis). One-year survival for 
/\ 
these indications is over 75%. 
r-. 
I 
Eight patients have been transplanted for Budd-,Chiari syndrome with 
, A 
_ J 
tour survivors, all on permanent anU;x..ulation. Extensive thrombectomy of V 
~ Cerilli: Transplantation Surgery 14~B 
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the portal system, the vena cava", and Uiotemoral veins may be required. Use 
../ 
of the venous bypass can be hazardous in this group of patients. After 
transplantation, these patients should be kept on permanent anticoagulation 
therapy. 
Seven patients have been transplanted for acute hepatic necrosis. Four 
+h1N 
patients have survived, including,* patients now more than 2 years since 
l\ 
transplantation. There is a chance of survival if patients are not in deep 
coma at the time ot surgery or have been in coma only brien,.. v 
/1\ 
\.!) SELECTION AND PREPARATION OF PATIENTS FOR TRANSPLANTATION 
y~F:F Since liver transplantation is a complex procedure ..... it is often assumed 
..) 
" that the evaluation and preparation of patients for surgery must also be com:! 
. ~ 
plex. In fact, the evaluation of liver transplant candidates can often be ae+ 
:J . --
complished quickl,. and at minimlHll expense if the immediate needs of the pat 
, -
tient are not confused with the research interests ot the physicians. Moat 
patients are referred to the transplant center with an established diagnosis 
and a poor prognosis without transplantation. A major gastrointestinal bleed, 
a history of repeated bouts of encephalopathy, progressive neuropathy, 
refractory ascites, a recent precipitous deterioration in liver function (e .•• , a 
recent increase in the rate of rise of serum bUirubin), poor hepatic synthetic 
function (low serum albumin and elevated prothrombin time), rapid progression 
of bone disease, and severe wasting are indications for early transplantation. V 
,---
Many of these patients have been needlessly explored and subjected to 
'" 
useless if not mutilating biliary tract operations, questionable porto!Fsystemtc 
...... 
v 
venous shunting. or unnecessary cholecystectomy or splenectom,.. Variceal 
14~9 
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bleed in, in patients awaitin, transplantation is a common problem but can 
V' -
.L ~DD; v...f. cJv 
usually be managed by sclerotherapy. In the rare case -where a venous shunt 
~K ..-., ~Cy+hs +~"gF ~ocoKKKftg ':;I,.,(,t, 
is required, meso~val or sPleno!renal shuntS ~ should be don~y?fflt-porto-cavai 
- ,.... 
-<:shunts. Splenectomy in patients with advanced cirrhosis and portal hypertent 
sion oft.en results in portal vein thrombosis and may ruin the patient's 
~ 
\ chances for successful transplantation. Percutaneous needle biopsy is suffi± 
I 
\ clent tor tissue dla,nosis in nearly all patients • 
. - ./ 1" -
__ ~":Eyf"h1 +FE~rE1f~~_ ----
){ CT) scans are useful to detect the presence of tumors, with or without 
extrahepatic extension. Laparotomy to rule out extrahepatic metastatic disease 
in candid~tes for transplantation for primary liver cancer is best carried out 
J:tI.at 
at the time the patient is taken to the operatin, room for transplantation. U 
A. 
extrahepatic spread of disease is found, a backup candidate can then be 
quickly substituted. 
""' A general evaluation of pulmonary, renal" and cardiac function is appror 
~ ~ 
priate to assess sur,ieal risk and prepare the patient for sur,ery. Portal 
vein patency can be assessed by non±invasive ultraUMundK~ We reserve inva! 
sive angiographic studies for patients whose portal vein cannot be visualized 
by ultraBOund or in patients with previous venous shunts in whom it fs 
important to assess the status of both the shunt and the portal vein. 
~ ,.... 
The patient's weil'ht, height, ABO blood I'roup,. and ultrasound measure±.. 
J 
""' ments of liver size are important in donor selection. Moat patients with post.:'! 
necrotic cirrhosis have a small liver,. whereas patients with seJerosinc choJan.f 
..J 
aitts and primary biliary cirrhosis usually have substantial hepatomepl,.. 
Liver transplantation can be successfully done across ABO blood ,roups and '" 
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in the presence ot pre;:tormed antf;:·donor antibody without significant risk 01 
'-
hyperacute rejection. Survival of .rafts in patients wfth preformed anti~ r-.. 
K:c~ 
donor antibody or high panel reactive antibody (Fig .. P) is the same or better 
than survival of gratts In patients without antibodyK~ However, long::.., term 
3s:: tJ,Cl.t " 
gratt survival tor ABO matched gratts (Fig 10) has been better than for ABO 
o~ A 
compatible but non:::identical or ABO incompatible grattsK~ Thus, we 
recommend that ABO compatible donors be used except in urgent situations or 
tor young children where donor availability is a critical problem. 
. ,...--......, 
The improved patient survival offered with cyclosporlne has encouraged 
~ 
referral of better candidates and has expanded the indications tor liver tran8;' 
plantation. ~ example, just a tew years ago, liver transplantation was lim£ 
yo ..... r,·.q -hY\(\ 
I ited to patients ~ 65 years of age. However, survival ot the 41 patients 
slf~D c tkVj . ...J 
-over 50 years 01 age in our tirst 500 cyclosporine:::treated patients has been 
~ \ ' . '\ 
. . i~-
Just as ~ as survival tor 256 patients between 18 and 49 ~earU KI~ 4,0) • 
.. A.J.t"'-tJ I~~K cL 
Six ot the !f; patients over the age ot 60 t\have survived, including one patient 
67 years old at the time of transplantation. tI 
II 
7 Predicting which patients will succeed and, whic~ will tail based on prei GV ./ KtA~M Gf\ -I '" ::''',-I(\tc.) ~ 
operative risk factors is difficult, Shaw recently performed a retrospective 
.A 0'\ D1~ --
analysis ot 118 liver transplantations in Pittsburgh over a .feW--year period to 
determine whether survival in the first ~ months could be p:edicted on the 
". 
basis of preoperative condition • .,<r- Variables coded in the analysis included 
mental status, malnutrition, ascites, previous surgerT, and complications 
(variceal bleeding. biliary sepsis, or spontaneous bacterial peritonitis). 
Operative blood bla was al80 analyzed. The analysis produced a slamoidal 
~ curv~ with most patients on the steep slope of the curve between infiecUon 
Ceriili: T 
ransPlJntation S 
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1 
,-_. __ .. -_ .. _------, 
point.s. Thus, it is difficult. ,10r most. paUentsto predict early outcome based 
·"-C-"-- -'''----------9) ,... 
on these preoperative factor!?).. Patients in deep coma at the time of trans! 
plantation, however, rarely survive unless their condition can be improved to 
I~ 
the point that they are awake and off the respirator when taken to the oper! 
ating room. Nevertheless, even patients in acute hepatic failure and coma 
have survived if transplanted quickly. 
,,--
'-
Given this unpredictability of survival, we continue to select patients 
for transplantation based on liver size, ABO blood group, and medical urgency. 
Only patients in deep, irreversible, subacute or chronic coma have little $ 
chance ot survival. 
ORGAN PROCUREMENT 
The development of effective techniques for multiple organ recovery haa 
, ~ V 
been essent.tal to the expansion of renal, liver and heart transplantation.lf• u. 3'f 
:; 
-:;;'-M- An insufficient supply of brain':.dead organ donors remains the single 
greatest limiting factor in solid organ transplantation. 
\.....;... 
Public awareness of the progress in organ transplantation and the need 
for organ donors has resulted trom media attention, professionally sponsored 
--. 
educational programs, and government interest. Our voluntary system of or+ 
gan donation has tor the moat part worked well. The public's response has 
been highly supportive" but significant resistance to organ donation has come 
...J 
.-
from physician apathy or reluctance to raise the issue of donation wit.h poteni' 
'-
tial donor famOles. Legislation to require hospitals to request permission for 
,.. 
organ donation has been passed in several states in the past year and is un+ 
Or/li<r St<lf.s ,"- V -
der active consideration by many ""'I8QN 
.A 
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TECHNICAL CONSIDERATIONS 
A well-=preserved, promptly functioning allograft is essential for V 
.::UtJ.t 
successful liver transplantation. Techniques have been developed whloh 
permit the liver, kidneys and thoracic viscera to be obtained from a single 
~ -
..-donor .... II ~
..) 
In the traditional procurement technique, the abdomen and thorax are 
entered through a complete midline sternal spr~ti~ incision. The lett lateral 
KAK~ 
segment of the liver is mobilized and the aorta encircled just above or below 
/- ./\ 
the diaphragm_ J. :-
Great care must be taken to identify and deal with the trequent 
variations In hepatic arterial supply_ The gastrohepatic ligament is palpated 
and inspected tor the presence of a branch of the lett aastric artery to the 
3$:: 
liver E~g1F which, if present, is preserved by dissection of the lett gast.ric 
artery back to ita origin trom the celiac axia. The division of the lett gastric 
artery to the greater curvature of the stomach can then be sately ligated and 
divided. The right hepatic artery (or, rarely, the common hepatic artery) may 
originate from the auperior mesenteric artery and lie posterior to the portal 
vein. This artery must be preserved in continuity with the proximal auperior 
mesenteric arter1. p~lal technique. have been developed for reconstruction 
gsD~ 
'v of Hvers with multiple arteries (Fi,,,l1).e-
14 ti ,,, 
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Once the preliminary dissection is completed, cannulas are inserted in 
the abdominal aorta and interior vena cava and cold Ringer's lactate is slowly 
~K r. ·'0" +~ 3.:;-:: 
..... --- ,"'.,; '- - "' 
intused through the portal vein cannula to cool the donor to D~;POKKM~ Em~ }2). 
~~- -. . 
The central venous pressure and consistency of the liver are carefully 
monitored and the inferior vena cava cannula is opened as needed to remove ,. 
J 
excess volume and prevent hepatic congestion. Once the Uver is cool, or if 
the donor becomes unstable, the aorta is crossclamped at the diaphragm and 
~ 
cold Collins,.., solution is infused through the aortic and portal vein cannulas. 
The inferior vena cava is divided at its junction with the right atrium. 
After a brief but thorough flush of the Uver, the aorta is divided 
proximal and distal to the origin of the hepatic arterial supply taking care not 
to injure the renal arteries. A clamp is placed just proximal to the renal 
vessels to permit continued cold perfusion of the kidneys atter division of the 
upper aorta. The diaphragm is cut leaving a wide cuff containing the 
suprahepatic vena cava. The intrahepatic vena cava is then mobilized and 
entered anteriorly Just above the renal veins. The orifices of the renal veins 
can be seen inside the opened vena cav,- which is then sately divided. The 
...J 
V 
liver is taken to the back table, given a final flush of Collins solution through 
.A 
the portal vein, and packaged for transfer to the recipient hospital. 
~ 
The kidneys can be rapidly e:;-aed en~blocvKnd separated on the back 
table. The left renal vein i8 divided at ita oriafn trom the vena cava. The 
vena cava should not be split In half, but rather should be left intact 
',- attached to the ~ht renal vein for use in providing additional length. 
C€rilli: qransplani~tion Surgery. 
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The Blr~iliac arteries and the iliac veins are also harvested. These 
grafts are often necessary tor reconstruction of the arterial supply and portal 
vein in recipients with inadequate native vessels. niac vein segments can also 
be grafted to tithe right renal vetn to add length during transplantation of the 
right kidney. 
The standard technique of procurement can be modified to permit rapid 
removal ot the liver as may be necessary in an unstable donorK~ No 
preliminary dissection is performed except encirclement of the proximal aorta 
and placement ot distal aortic and vena cava cannulae. If the heart fa to be 
taken, it is then prepare~ and" when the thoracic team is ready to arrest 
..,) ~ . 
circulation, the proximal aorta is crossclamped. A rapid infusion ot cold 
~ ~ 
Collins solution is then begun through the aortic cannula (Fist 13). The ~ ~~ 
interior vena cava is divided at its junction with the right atrium. The heart 
is then removed while the liver continues to flush. The intestines and portal 
vein ~ n~:ch within 2 to 3 minute~ and the liver will be palpably cold. In 
adults, 2 to 3 liters ot flush are sutficient to cool the liver to a 
"" (/ ely- '." I .,;::;j -
---... :..-.. "_.', 
cryoprotective temperature ot less than 2a,J. Once this has been achieved, 
the aortic flush is slowed and the hepatic arterial supply and hilum u. 
dissected in a bloodless field. The same care must be taken to identity and 
preserve arterial anomalies as with the standard technique. The liver is then 
excised in a manner similar to the standard methoct leaving a cuff of 
..;; 
diaphragm and the adrenal .land attached to the hepatic portion of the vena 
cava. In experienced hande, the donor hepatectomy can be performed in onlT 
halt an hour by thia method. v/ 
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The tinal preparation of the allo~raft occurs on a back table in the 
recipient operating room. The adrenal gland and excess diaphragm are 
removed and the vascular cuffs are prepared for anastomosis. All technical 
" .;> 
anomalies are reported to the recipient surgeon 80 that he may make an,. 
changes in recipient technique necessary to accommodate the graft. 
The recipient hepatectomy is often the most difficult part of the Uver 
transplant procedu~ and there is no single best. method. Individual 
dissection of hepatic hilar structures may be impossible because of previous 
surgery or because of massive formation of varices. Mobilization of the Uver 
from the hepatic fossa may result in massive hemorrhage it the hepatic 
arterial and portal venous blood supply have riot. first been controlled. 
,.-------... 
Occlusion of the vena cava and portal vein without bypass may result in 
cardiovascular Instability, splanchnic and renal venous hypertension, and 
Increased hemorrha~e from thin:.walled venous collaterals. Since 1983 we have s 
-
routinely used a pump=;;driven ven~venous bypass system without systemic 
heparinization durin~ the anhepatic phase of the recipient operation. w. 
believe that this has contributed to a significant reduction in morbidity and 
mortalitKy~ Use of the bypass has permitted JBOditications in the technique of 
recipient hepatectomy, decreased transfusion and ftuid requirements, and ret 
duced cardiopulmonary and renal complications.e, 
r--
When possible, the individual structures in the hepatic hilum are 
.... 
skeletonized, but no other dissection fa necessary. Bypass is then eatabUshed 
14 tJij 
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by placement of cannulas in the portal vein and saphenotfemoral vein. Return 
to the superior vena cava can usually be done through a cannula In the 
axillary vein. If the hilar dissection is difficult, a vascular clamp is placed 
3S":: 
across all the hilar structure~ which are then transected (Fi(}4). The 
..J 
individual structures are then identified, dissected back, and the portal vein 
is cannulated. V 
Division and cannulation of the portal vein greatly faciUtates mobilization 
of the liver from the hepatic fossa and dissect.lon of the infra hepatic vena 
cava. The triangular ligaments and and peritoneal reflections that make up 
the coronary Ugament are cut and the right lobe ot the liver is elevated into 
!; 
the wound. The suprahepatic and infrahepatic segments of the vena cava are 
then encircled. If it is not possible to encircle either the upper or lower 
J vena cava, the liver can be shelled out from above or below as shown in 
fM~fEb~ ':. _M_~;; gR~g/K"Io 
:.=' Fij'4o? andJ:e.).:--
--.. 
Once the liver has been removed, use of the ve~venous bypass 
. '-' 
Jrovide .. _time to close the raw areas created durin. the hepatectomy as 
r .- c. _. -,,-r IffyI~j \ ' K;K;~- I fC...) 
in ~ l'lr This will minimize bleeding during performance of the vascular 
anastomoses. Adequate vena cava cutts and sufficient. length of portal vein 
must have been developed before the araft is brought into the field tor 
I anastolDOlJi8. 
/ 
--i 
\ The anastomosis of the auprahepatie vena cava is performed tirat~ 
.:.> 
tollowed by the Intrahepatic vena cava. Near completion of the -tbl'lower cava 
anastomosis, the liver Is tlushed with cold lactated Ringer'. solution to remove 
V \, entrapped air and concentrated potassium. The portal bypass cannula i8 .. hen 
l;t.IUIi: qr<-!n~igi::KltKK::tion Surgery 
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'.' 
removed leaving t.he patient on vena cava bypass while the portal vein ill 
:; 
reconstructed. The liver is then revascularized with portal ~ and all 
..j 
~s 
remaining bypass cannula~ are removed. After reasonable hemostasis is 
v- , 
obtained, the hepatic artery Is reconstructed. 
Successful reconstruction of the portal venous and hepatic arterial 
circulations demands t1awless technique. Failure of either anastomosis usually 
leads to patient death or retransplantation. A modifled continuous suture 
technique with 6-0 or 7-0 polypropylene suture is used such that the knot Is 
tied a significant distance from the vessel wall.e.. This permits the vessel to 
distend to tull caliber as the suture recedes back into the vessel and 
redistributes itselt after restoration of now. A single interrupted suture 
placed where the two ends of the oontinuous suture meet prevents separation 
35"::: 
of the vessel at the growth faCtor (Fig 18). 
. (:) 1\ 
Direct anastomosis of the graft to the recipient hepatic artery fa often 
not possible becau. of inadequate size, dtseaae, or injury ot the native 
artery. Alternative methods of reconstruction must be used in these casesK~ 
~ ~g 
Our preferred method Is to usecf a segment. of donor lllac artery "Wf:\ich ill 
anastomosed to the infrarenal aorta and tunneled under the pancreas and 
duodenum to reach the gratt. Conduit. of donor aorta lett In continult,. with 
the celiac axis and hepatic artery and anastomosed to the recipient fntrarenal 
aorta have al80 been used in email chUdren. 
Betore the billary reconstruction is attempted, complete hemostasis 
should be obtained. In recent years direct duct: to -duct reconstruction over a 
~ " _'I.. Pp~- J 
~tube (Fit }9t' has been our preferred method ot biliary reconstruction. 
'\, 
, 
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When this is not possible, such as in patients with disease of the extrahepatic 
biliary system, Roux=-en;;.Y choledochojeJunostomy over an internal stant fs 
used Ecii~19y~F • .j 
~Dct POSTOPERATIVE CARE AND COMPLICATIONS 
Mtar surgery" initial care is similar to that for: other patient. 
undergoing a major general surgical procedure. The patient is kept in 
t/,,--I.Jl M :;/1 ~K 
intensive care until"alert, extubated, and hemodynamically stable. Many 
patients are ready to return to the regular hospital floor within 48 hour. 
after transplantation. Antibiotic prophylaxis tor biliary tract oracanisms 
t/ t:-DI"D~~i;EhiClKKK 
EhlebsieliaI-i"Coli~- and enterococci) is begun before surgery and continued for 
---- .-.-
5 days. 
Nearly all patients leave the operating room with a significant excess of 
KfD~ If = !3.--flui~ and most patients will have oliguria in the tfrst-af"48:. hour period. 
Diuretics and colloid are often required. Vigorous use of crystalloid can 
easily result:tb, ~:"I~:nary edema. Fresh frozen plasma (FFP) should be used 
with restraint trifte& overzealous correction of clotting parameters may 5 " 
contribute to postoperative hepatic artery thrombosis. We generally avoid use 
of FFP unless the prothrombin time fs persistently over 25 seconds or there t. 
evidence ot major ongoirig blood los8 with abnormal clotting parameter •• 
r-' 
It is beat to give potassium as bolus when needed rather than add it to 
VJ.'" f"D~I1f () ('I,4.S 
the maintenance j f¥ fluids. draf~ necrosis (primary non~function or hepatic 
~predictable 
artery thrombosis) can result in sy:ddMl increases in serum potassium. 
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Children can rapidly develop low ionized calcium levels and hy~ or 
hyperglycemia atter liver transplantation. Thus, glucose and ionized calcium 
levels must be monitored closely during the first 48 hours. 
,.-.... 
Mental status, prothrombin time, and urine output are important 
indicators of \he quality of early graft function. Narcotic and other 
J...j.at 
medications which may interfere with the evaluation of mental status are 
,'\ 
contraindicated. Primary graft failure occurs infrequently but is a very &ej, 
rious complication. The patient decompensates quickly and will show markedly 
~~"irE"~C MfIlOU; s"r:,t't1'\ " 
--., ~%I 'W.---
abnormal liver function, coagulopathy, oliguria, and severe1~ eNS'; changes. 
Stage IV coma, alkalosis, hyperkalemia, and hypoglycemia characterize the 
terminal phase of J;his acute hepatic decompensation. Avoid giving any 
FFP 
po~ssiumI give fr4HJb.-lrozen.-,pJasma every 4 to 6 hours, and keep the gastric 
" more ' 
PH-INa than 5. Urgent retransplantation is r~quiredK 
- ' 1\ , 
Hypertension is a common problem in the postoperative patient. 
,. r-
Hydralazine and beta-blockers (labetalol, proP..8nolol) are first-=Une drugs. 
" " 
MinoxidU (Loniten), clonidine (Catapres), and captopril (Capoten, often 
preferred for children) are alternatives in patients requiring other agents. 
Avoid methyldopa (Aldomet)", which is hepatotoxic. Intravenous nitroglycerine 
oJ KAK-?~11 " ,/(" ~ ~ 'IS fKt/Dt-~ 1. u ..... 
can be used when appropriate for patients in the lOUr Sodium nitroprusside 
.... 
must be used with caution because of the potential for cyanide toxicity. 
Nifedipine (Procardia), 10 mg, administered under the tongue, is useful in an 
emergency. 
In cases of refractory hypertension, labetalol (trandate normodyne), a 
v beta- and alpha;.; adrenertric blocking drug with &elective action on peripheral 
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vascular receptors, can be given intravenously. The drug must be given by a 
physician with continuous blood pressure monitoring in the intensive care 
unit. It is given in J,<;t120;,.mg doses over 2 minutes and may be repeated 
every 10 minutes up to a total of 300 mg or can be administered as a 
continuous intravenous infusion at 2 mglmin, adjusted according to the blood 
pressure. ( 
fm~unosuppressiod and ReJection 
Cycl08porine therapy has been discussed previously. Patients with 
persistent oliguria or elevated serum creatinine require reduction of 
cyclosporine dosage. In cases of severe renal failure, cyclosporine is 
discontinued and treatment with monoclonal OKT=3 antibody is substituted tor 
02 
as long as ~ weeJts to allow renal function to recover. 
,,--
'--I 5 ,,-, . 
The patient is given Ofte ..... ~I methylprednisolone intraoperatively 
and then begun on a steroid taper after surgery. Adults are begun on 200 
mg per day given in (f diVided doses and tapered 40 mg per day until a 
maintenance dose of 20 mg per day is reached. Children are begun at 100 mg 
VGJU... 
per day and tapered by 20 mg per day. Very small chUdren are maintained 
./\ 
1T\'1 .:jo 
on only 1~rRmg per day. As soon as oral intake is established, oral 
prednisone is substituted for the intravenous steroid. ." 
~ 
Hyperacute rejection of t~e Uver is a controversial entity rand, it it 
exists, is a rare event. Acute allograft rejection usually occurs 'I to 21 da,.. 
0/ after operaron~ but can occur at any tilDe. Barly "accelerated" rejection I. 
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occasionally seen. Liver biopsy may be required to dis-tinguish between early 
rejection and ischemic injury. 
I'" 
Rejection is most commonly manifested by malaise, fever, graft swelling 
and tendernesa, and diminished graft function. A rise in bilirubin and 
transaminases is usually Been and T-tube biliary drainage may be thin and 
I :3 light in color. Clinical rejection is treated initially by a 9R8 "rem IV bolus of 
" 
methylprednisolone followed by a complete recycle of the postoperative steroid 
taper. If response is poor, biopsy and treatment with monoclonal antibodr 
should be considered. 
Monoclonal mouse anti-human thymocyte globulin (OKT=3) has been 
approved for cUnical use by the U.S. Food and Drug Adminislration. It is 
used for the treat~ent of acute Uteroid~resistant rejection or tor sparing of 
cyclosporine in toxic patients. It is "iven as a single daily dose of 5 m" IV 
over 5 m~:~:;s EOKR-1f~+!n children less than 30 ;l~;ctt~Di~~f~~~gKsolucortef 
are given M~ to .. reduce unpleasant reactions. ,,{CBg, hematocrit, platelet 
count, and q~ell ratios are monitored during therapy. 
Chills and fever are common with the firat few doses ot OKT-3. 
Bronchospasm, hypotension, cheat pain, nausea, vomiting, and diarrhea may 
also occur. Pulmonarr .edema can occur in patients who are fiuid overloaded. 
Acute respiratory aymptoms ("anaphylactoid reactions") or anaphylaxia, 
manifeated by joinl paina, ahorlneaa ot breath, and hypotension, may occur 
and require atopping the drug and administering epinephrine, ateroids, and 
Ccnlli; Trall::>!-lli;lnl..ltion S"'lgery 
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Therapy is ~ usually continued for 10 to 14 days. Patients may develop 
antibodies to the mouse protein with subsequent loss of efficacy. / 
Infection is responsible for much of the morbidity and mortality after 
liver transplantation and it can be difficult to distinguish reject.ion from 
$ 
postoperative viral hepatitis. Cytomegalovirus (CMV) infection of the liver fa 
the most common troublesome offender.e- It is diagnosed by serologic changes 
and/or isolation of the virus. Liver biopsy may show the typical inclusion 
bodies in the hepatocytes but biopsy material should always be cultured. 
S 
/ 
be ~ ED~K /lH.' d; -'I 
CMV infection m~~primaryI as established by seroconversion, or ~ . v-
.--. 
reactivation of prior infection, as documented by a four told or ,reater rise in 
antibody titer. Many CMV infections are self=limited if immunosuppression is 
managed with rest.raint. Steroid maintenance should be reduced and 
cyclosporine levels kept as low 88 possible. 
,-'---"'., 
Hepatitis Bt'virus, adenov:'us, and herpes virus are other less common 
offenders. Hepatit1st'B is also often self-limited and managed by reduced 
immunosuppressive therapy. Herpes and adenovirus graft hepatitis have a 
poorer prognosis,. and early retransplantation may offer the best chance of 
survival for pat~nts with these infections. ~ 
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Surgical mortality (death within 30 days of operation) has significantly 
JS .. 
declined aince 1980 and ia currently less than 10% (Fit r»' Technical 
complications are still responsible for a significant portion of the morbidity 
and mortality aftar liver transplantation. Our first 393 transplantati!>ns in 313 
(1.(,.J ~"f;KDycDl r. g~_ffD ~KK _ -0"" 
cyclosporine~treated pa~K!lKts ~e~~_K~ent1y reviewed by ieruI~ '.otn 393 
~ .. I~~iD:D .-.- ... ---.... .. ..... . -__ E~: 
transplantations there were; 87 (22.1%)" technical complicationsl\with 24 directly 
.:; ----·----_.:::1.) 
related deaths, including 52 biliary tract complications (13.2%) responsible for 
5 deaths and 27 hepatic artery thromboses (6.8%) responsible for 16 deaths. 
Direct duct·~to -duct biliary reconstruction over a T.=tube or Roux=-en.:.Y 
" " v. 0/ -t.)l\.,c;.I 
choledochojejunostomy over and internal stant ~ successful in 305 of 334 
, 
(91.3%) grafts. Failures of duc~ to~KIduct reconstruction are best managed by 
,.-.. 
conversion to ooux~n;;Kv choledochotjejunostomy. 
--
-Hepatic arterial thrombosis is the most common technical complication ref 
Quiring retransplantation and accounts for nearly 40% of the retransplanta+ 
-:,. tI -
tions in children (Fi\21). It. is the most common indication for retrans~ 
1:.(,lA'" r;c r t~~K ,"-" 
J v, I~~~~K~~n in children ~ 2 years of age. aes~~_:ipI survival of children 
- .uftder 2 years of age has been no ditferent than ffr~ of older children 
3s: 
Eci~~BFK 
Fever with gram -:negative septicemia is almost pathognomonic of hepatic 
" 
artery thrombosis" and the clinical presentation ,enerally follows one of three 
.) 
patterns: acute hepatic gan,rene, delayed biliary fistula, or relapsing 
bactaremiaK~ The ischemic injury to the biliary tree often results 
147':1 
./ 
14S5 
_.i I ...1--( ..... 
i / ... ~ -~ intrahepatic abscess formation or biliary fistula. Doppler ultrasound studies 
//" -\ 
--1/'"" ) 
v 
are useful in assessing the patency of the hepatic arteryK~ It pulsations are 
not well visualized, an arteriogram 1s indicated. Ultrasound or CT scans may 
demonstrate abscesses in the hepatic parenchyma. A few patients, mostl7 
small children, have survived hepatic artery thrombosis without 
retransplantation, but for most patients, replacement of the graft is 
-' 
eventually, if not urgently, required. 
/ 
::;: o~ 
RETRANSPLANTATION 
In our first. 500 cyclosporine t.reated patients, 147 (22.7%) have required 
~ ~ 
retransplantation for allograft rejection (53.1%), technical complications (27.9%), 
r 
or primary graft failure E19KM%rEc~ 21). Fort.unately, survival after re-+ 
. ..., ~ .. ~ 
transplantation has also improved. Patient sur:vival after retransplantation for 
I (-<; 
loss of a first. tKranB~~~D :eKgr~~1geBs ,Of cause, ~~-:4S~4% at. on.e year.:; and tor 
loss of a second graft,. is 53.4% at one year (Fig 22tA). 
'\ -...:,' '-
_ . .-/ 1=='"' 
For patient.s retransplant.ed for loss of a first graft. to rejection, ~ 
-
year survival is 59.5%/, and, for technical failures (mostly hepatic artery throm-r 
It 4!:--' - ~K . ~ -
bosis), is 43.1% (Fig OO~BFK Primary non;;function is a devastating complicat.ion, II ""_ _ _. 
since the patient ia in acute hepatic fanure, ia often septic, and 1a in urgent 
need of anot.her liver. One year aurvival aft.er retransplantat.ion for primary 
" ;.,... '-. 
..... _..,.)::'" tl. 
failure of a first transplant ia only 27.4% (Fig 22,8). 
CONCLUSION 
" --' I It, .::' ~ t,' _ l~·I 
)1"11e past fire 788rS .... batt-seen liver transplantation accepted as the 
A -' ~ 
/ 
treatment. of choice for most. causea of end stage liver tailure in children and 
. \ 
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adults. Many major commercial and Blue Cross medical insurance programs 
now provide coverage tor this procedure. Most ot the patients who survive 
I 
the operation return to a relatively normal lifestyle within one year of operaf 
/\ .-
~ 
tiona Although the Immediate costs of the operation are considerable, avera"i 
\ ing over $150,000 for medical costs and family expenses, the reward is alao 
\ / 
I high. Death from Hver failure is Krexme!D1K~Di;; al:O\ and nothin" is returned to 
I~ -K~I" .' 
\ 
\ 
society. Most of the patients who require liver transplantation are either 
children soon to enter or adults In the productive years ot life. The worth to 
society ot the advances in knowledge that have and will continue to accrue 
from programs in organ transplantation are incalculable. 
Liver transplantation is otten cited by critics as an example of "hiKgh~" 
tech" medicin~ which contributes to the escalation of health care costa. 
Luebs,!/ has replied, "when the cost of health care in our society is attacked 
as being too high, one must ask "compared to what?" Is it too high compared 
with the cost of national drug and alcohol consumption? Is it too high com-t 
pared with our nation's defense bill or our payment of interest on the national 
debt? •• the true coat of health care, although taking a large portion of our 
nation's gross national product, is reasonable in a society concerned with 
suttering and the quaHtr of ute." 
-Organ transplantation depends upon public goodwOl since it is the pub,-Q) -
Ue that provides both essential reaource~Iy money and organs. The public's 
enthusiastic aupport 01 organ donation and its charitable financial support 01 
transplantation programs Is a clear signal that the nation has not loat ita tra-t 
ditional commitment to the relief of individual sufferin,. 
d~_D~:~~E~~ 
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